Results 111 to 120 of about 31,972 (221)

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Interrelationships among handgrip strength, body composition, physical activity, and quality of life in adults with cystic fibrosis: A cross‐sectional study

Nutrition in Clinical Practice, Volume 41, Issue 3, Page 849-858, June 2026.
Abstract Background In individuals with cystic fibrosis (CF), lean mass and muscle strength are important predictors of clinical outcomes. This study evaluated associations among body composition, handgrip strength, muscle quality, physical activity, and health‐related quality of life in CF. Methods This observational, cross‐sectional study included 27
Benjamin H. Crain, Carly Harris, Moriah P. Bellissimo, Lucia A. Gonzalez Ramirez, Elizabeth A. Ivie, William R. Hunt, Vin Tangpricha, Thomas R. Ziegler, Ryan A. Harris, Jessica A. Alvarez   +9 more
wiley   +1 more source

Clinical Use of Home Spirometry in Children With Cystic Fibrosis

Pediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Background The use of home spirometry (HSPIR) has increased in pediatric cystic fibrosis (CF) care, but how it has been used clinically and its impact on clinical care have not been described. The purpose of this study was to address this knowledge gap through a secondary analysis of data from a HSPIR quality improvement project to ...
Lucy Tan, Andrew Borowiec, James A. Reed, Mark Rath, Reid Masi, Laura Bennett, Don B. Sanders, Daniel J. Weiner, Clement L. Ren   +8 more
wiley   +1 more source

Late Onset Telomere Biology Disorder Presenting With Pancytopenia, Immune Dysregulation, Interstitial Lung Disease and Alopecia

American Journal of Hematology, Volume 101, Issue 6, Page 1196-1200, June 2026.
Bo A. Wan, Hamish Nicolson, Heather A. Leitch, Ryan J. Stubbins, Luke Y. C. Chen, Timothy Murray, Amy Trottier, Anthony Gador   +7 more
wiley   +1 more source

Performance Evaluation of a Novel Cystic Fibrosis Caregiver Burden Measure Demonstrates Significant Challenges for Parents of Children With CF During the Early Years: The Irish Comparative Outcomes Study (ICOS)

Pediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Background As a part of the Irish Comparative Outcome national cohort study of childhood CF, this cross‐sectional study investigated challenges faced by parents of children with CF (CWCF) in the Republic of Ireland using a newly validated modified tool. Methods Parents completed the modified “Challenge of Living with Cystic Fibrosis‐Short Form”
Rini Bhatnagar, Nancy Bhardwaj, Gwinyai Masukume, Ricardo Segurado, Barry Linnane, Mary Herzig, Muireann Ni Chronin, David Mullane, Des W. Cox, Paul McNally, Sheila Javadpour, Ruth O'Reilly, Basil Elnazir, Peter Greally, Fiona Healy, Michael Williamson, Dubhfeasa Slattery, Gareth McCray, Gillian Lancaster, Claire Glasscoe, Kevin W. Southern, Laura Kirwan, Patricia Fitzpatrick   +22 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.
ABSTRACT Ivacaftor is the only cystic fibrosis transmembrane conductance regulator modulator approved for infants ≥ 1 month. The elexacaftor/tezacaftor/ivacaftor combination, approved for children aged ≥ 2 years, has been shown to significantly slow CF progression.
Ngoc Hoa Truong, Sihem Benaboud, Naïm Bouazza, Eric Deneuville, Anne Mornand, Philippe Reix, Mélanie Ribault, Pierre‐Régis Burgel, Léo Froelicher‐Bournaud, Steeve Rouillon, Mohammed Rohi Sanoufi, Gabrielle Lui, Saïk Urien, Jean‐Marc Tréluyer, Isabelle Sermet‐Gaudelus, Frantz Foissac, Modul‐CF study group, Melissa Baravalle, Mahassen Barboura, Lilia Benhalla, Khadidja Bennour, Katia Bessaci, Antoine Bessou, Thiphaine Bihouée, Anne‐Sophie Bonnel, Nesrine Bouleghem, Stéphanie Bui, Frédérique Chedevergne, Harriet Corvol, Laure Cosson, Laure Couderc, Marie‐Laure Dalphin, Paola De Carli, Eric Deneuville, Pierre Foucaud, Asma Gabsi, Elsa Gachelin, Fatiha Hassani, Véronique Houdouin, Frédéric Huet, Marie Jamin, Kadiatou Kaba, Guillaume Labbé, Jane Languepin, Muriel Laurans, Cathy Léréna, Alexia Letierce, Clotilde Livrozet, Christophe Marguet, Laurent Mély, Rania Messaoudi, Marie Mittaine, Camille Ohlmann, Caroline Périsson, Thomas Perrin, Carole Piccini‐Bailly, Cinthia Rames, Philippe Reix, Natascha Rémus, Anna Ronayette, Djouher Sahki, Manuela Scalbert, Isabelle Sermet, Floriane Socchi, Nathalie Stremler, Aurélie Tatopoulos, Guillaume Thouvenin, Tom Toin, Françoise Troussier, Laurence Weiss, Marie‐Christine Werck‐Galois, Nathalie Wizla   +71 more
wiley   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, Volume 31, Issue 6, Page 561-577, June 2026.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

AEG‐AESPANC‐OPGE‐SIED‐SPG Ibero‐Latin American Guidelines on Acute Pancreatitis (iLATAM‐AP)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Introduction Acute pancreatitis (AP) is a major cause of gastrointestinal hospitalizations worldwide. Although typically self‐limiting, up to one‐third of cases develop complications associated with increased morbidity and mortality. Despite recent advances that have improved outcomes, clinical heterogeneity necessitates updated, evidence ...
Karina Cárdenas‐Jaén, Lucía Guilabert, Emma Martínez‐Moneo, Carla Mancilla, Miguel Bispo, Pedro Moutinho‐Ribeiro, Rodrigo Mansilla, Andreia Rei, Ana García García de Paredes, Antonio López‐Serrano, Bruno Rosa, Claudia Sánchez‐Marín, Daniel de la Iglesia, Edson Guzmán‐Calderon, Eduardo Rodrigues‐Pinto, Eva Marín‐Serrano, Fabio Ausania, Fauze Maluf‐Filho, Guido Villagómez, Humberto Cristino, Isabel Pascual‐Moreno, José A. Gonzalez, José M. Ramia, João Lopes‐Delgado, Lucas Granero, Mario Peláez‐Luna, María Francisco, Natalia Corzo‐Zamora, Ricardo Rio‐Tinto, Rómulo D. Vargas, Sandra Basso, Susana Lopes, Susana Marques, William Manzanares, Zoltán Berger, Irene Carrillo, José Joaquín Mira‐Solves, Alberto Espino, Adriana Cowdin, Alejandro Piscoya, Alexandra Fernandes, Noelia Rodríguez‐Ferreiro, Neftalí Jara Pérez‐López, Beatriz Valero, Enrique de‐Madaria   +44 more
wiley   +1 more source

Pregnancies in women with rare diseases: Selected maternal and perinatal outcomes

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 6, Page 1088-1095, June 2026.
Pregnancies in women with rare diseases carry substantial disease‐related (23.2%) and pregnancy‐specific (25.1%) risks. Complication rates drop markedly when conditions are stable before conception. Abstract Introduction Rare diseases (RD) are characterized by chronicity and may be associated with reduced life expectancy and quality of life.
Philipp Kosian, Kristin Niederhöfer, Elena Jost, Ulrich Gembruch, Tim Bender, Lorenz Grigull, Waltraut Maria Merz   +6 more
wiley   +1 more source

Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators

Acta Paediatrica, Volume 115, Issue 6, Page 1283-1289, June 2026.
ABSTRACT Aim Children with cystic fibrosis (CF) face substantial daily treatment burdens and the effects of transmembrane conductance regulator modulators on these have not been sufficiently described. We evaluated changes in treatment burden after elexacaftor tezacaftor ivacaftor (ETI) was initiated.
Marcus Svedberg, Frida Lundqvist, Huda Abdulahi Östrand, Christina Krantz, Per Ekman, Henrik Imberg   +5 more
wiley   +1 more source